Long COVID Patients Face Lingering Worrisome
Prolonged COVID is a series of symptoms that can last weeks or months after first being infected with the virus that triggers COVID-19 or can show up weeks after infection. Long COVID can take place with any individual that has had COVID-19, even if their ailment was moderate, or if they had no signs and symptoms.
Top Pfizer, Moderna execs at odds on need for 4th COVID-19 vaccine dose
Top executives at pandemic juggernauts Pfizer and Moderna are at odds on the need for a fourth COVID-19 vaccine dose. | Top executives at pandemic juggernauts Pfizer and Moderna are at odds on the need for a fourth COVID-19 vaccine dose. One says a sec...
Targeting GSK and AstraZeneca, Clovis lifts sinking Rubraca with broad ovarian cancer win
Under siege from rival drugs by GlaxoSmithKline and AstraZeneca, Clovis Oncology’s Rubraca faces an existential crisis. | Under siege from rival drugs by GlaxoSmithKline and AstraZeneca, Clovis Oncology’s Rubraca posted a much-needed win in a broad ova...
Patients With Long Covid Face Lingering Worrisome Health Risks, Study Finds
Patients who were not sick enough to be hospitalized still had a significantly greater risk of dying within six months than people who were not infected.
After FDA green lights a second COVID booster, official says another could come in the ...
A few hours after the FDA authorized a fourth dose of the Moderna and Pfi | A few hours after the FDA authorized a fourth dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines, one of its top experts, Peter Marks, hinted that a fifth dose may be on...
'In the long-term interests': FDA oncology chief defends rejection of Lilly, Innovent c...
In a largely expected yet widely debated decision, the FDA
Bristol Myers Squibb's Revlimid finally faces competition in the U.S. with Teva's gener...
Sales of Bristol Myers Squibb’s Revlimid crescendoed at $12.8 billion in 2021, the final year of exclusivity for the multiple myeloma treatment. | Sales of Bristol Myers Squibb’s Revlimid crescendoed at $12.8 billion in 2021, the final year of exclusiv...
In a year of big growth for AbbVie, CEO Richard Gonzalez scored $24M pay package
During a year in which AbbVie pulled off a remarkable feat—increasing revenue by 23% without the benefit of a major COVID-19 product—the company rewarded CEO and Chairman Rick Gonzalez with a pay p | During a year in which AbbVie pulled off a remarkabl...
High-risk lung cancer patients aren’t getting screened, survey shows. What can the indu...
Early diagnosis can make a huge difference in outcomes for lung cancer patients, and screening is particularly important for patients who are considered high-risk. | Early diagnosis can make a huge difference in the outcomes of high-risk lung cancer pa...
FDA accelerated approvals targeted for revamp in House Energy and Commerce committee ch...
The chairman of the House Committee on Energy and Commerce is taking the FDA’s accelerated approval pathway to task. | Frank Pallone Jr., D-New Jersey, unveiled the Accelerated Approval Integrity Act. “[U]nder the current system, some products have be...
Pfizer is halting investment in Russia but not ending its business there. Should drugma...
As a flood of major corporations from the West flee Russia in protest of its invasion of Ukraine, there is a glaring lack of participation from the pharmaceutical industry. | As a flood of major corporations from the West flee Russia in protest of its ...
'Extreme disappointment': With FDA snub of Akebia's vadadustat, another oral anemia med...
Is the much-hyped oral HIF-PH inhibitor class of drugs destined to disappoint? | The FDA has issued a complete response letter to Akebia and Otsuka, denying their bid for approval of vadadustat to treat anemia associated with chronic kidney disease. It...
Moderna seeks FDA nod for COVID vaccine in children under 6, starts delayed filing for ...
Moderna has new data backing the use of its COVID-19 vaccine Spikevax at a low dose in the youngest children under the age of 6, and it’s moving forward with global regulatory submissions. | Moderna has new data backing the use of its COVID-19 vaccine ...
After layoffs, Gilead to build NJ hub that will employ up to 500
Earlier this month, Gilead Sciences said it planned to lay off 114 workers bas | Amid news that Gilead is closing a manufacturing site in northern New Jersey and laying off 114, the company said it is planning to build an East Coast corporate hub nearb...
As rivals eye 'unjustified royalties,' Pfizer partner sues to defend COVID-19 shot Comi...
Pfizer has already reeled in tens of billions of dollars in sales for its COVID-19 shot Comirnaty. | Pfizer has already reeled in tens of billions of dollars in sales for its COVID-19 shot Comirnaty. Now, one of the company's partners says rival compan...
In a busy month, Pfizer extends recall of blood pressure meds to the UK
Add another country to the recall list for Pfizer’s blood pressure medicines. | Pfizer has recalled one lot of its blood pressure medicine Accuretic in the U.K., continuing its busy month of voluntary recalls as a precautionary measure because of the p...
Pfizer CEO scored big raise—to $24M—as drugmaker played a leading role in pandemic fight
Pfizer has already made tens of billions of dollars in sales from its star COVID-19 vaccine, Comirnaty. | Pfizer has already made tens of billions of dollars in sales from its star COVID-19 vaccine, Comirnaty. For his work in steering the ship, the com...
Shock Therapy for Neoliberals | by Joseph E. Stiglitz - Project Syndicate
Joseph E. Stiglitz argues that two decades of systemic crises have made lingering free-market policy orthodoxy untenable.
Novavax, hoping to bump up its lagging European launch, asks EMA to authorize its COVID...
Novavax is looking for a swift green light in Europe to market its protein-based COVID vaccine Nuvaxovid in teenagers as take-up stalls in adults. | Novavax is looking for a swift green light in Europe to market its protein-based COVID vaccine Nuvaxovi...
The Role of Medical Billing and Coding Professionals
When you visit the doctor, you're likely to be asked about your health information. The healthcare industry handles a great deal of sensitive patient ..